1
|
Wiest J, Saedtler M, Balk A, Merget B, Widmer T, Bruhn H, Raccuglia M, Walid E, Picard F, Stopper H, Dekant W, Lühmann T, Sotriffer C, Galli B, Holzgrabe U, Meinel L. Mapping the pharmaceutical design space by amorphous ionic liquid strategies. J Control Release 2017; 268:314-322. [PMID: 29097303 DOI: 10.1016/j.jconrel.2017.10.040] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Revised: 10/27/2017] [Accepted: 10/28/2017] [Indexed: 01/12/2023]
Abstract
Poor water solubility of drugs fuels complex formulations and jeopardizes patient access to medication. Simplifying these complexities we systematically synthesized a library of 36 sterically demanding counterions and mapped the pharmaceutical design space for amorphous ionic liquid strategies for Selurampanel, a poorly water soluble drug used against migraine. Patients would benefit from a rapid uptake after oral administration to alleviate migraine symptoms. Therefore, we probed the ionic liquids for the flux, supersaturation period and hygroscopicity leading to algorithms linking molecular counterion descriptors to predicted pharmaceutical outcome. By that, 30- or 800-fold improvements of the supersaturation period and fluxes were achieved as were immediate to sustained release profiles through structural counterions' optimization compared to the crystalline free acid of Selurampanel. Guided by ionic liquid structure, in vivo profiles ranged from rapid bioavailability and high maximal plasma concentrations to sustained patterns. In conclusion, the study outlined and predicted the accessible pharmaceutical design space of amorphous ionic liquid based and excipient-free formulations pointing to the enormous pharmaceutical potential of ionic liquid designs.
Collapse
Affiliation(s)
- Johannes Wiest
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Marco Saedtler
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Anja Balk
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Benjamin Merget
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Toni Widmer
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Heike Bruhn
- Institute for Molecular Infection Biology (IMIB), Josef-Schneider-Straße 2, 97080 Würzburg, Germany
| | - Marc Raccuglia
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Elbast Walid
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Franck Picard
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Helga Stopper
- Department of Toxicology, Institute for Pharmacology and Toxicology, Versbacher Straße 9, 97078 Würzburg, Germany
| | - Wolfgang Dekant
- Department of Toxicology, Institute for Pharmacology and Toxicology, Versbacher Straße 9, 97078 Würzburg, Germany
| | - Tessa Lühmann
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Christoph Sotriffer
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Bruno Galli
- Novartis Pharma AG, Lichtstraße 35, 4002 Basel, Switzerland
| | - Ulrike Holzgrabe
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany
| | - Lorenz Meinel
- Institute for Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany.
| |
Collapse
|